Literature DB >> 16769157

Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.

Zhong Zhao1, Zhongmin Xiang, Vahram Haroutunian, Joseph D Buxbaum, Breton Stetka, Giulio Maria Pasinetti.   

Abstract

In this study we report that the membrane-bound, but not cytosolic insulin degrading enzyme (IDE) protein concentration and IDE activity are significantly decreased in the hippocampal formation of cases affected by mild cognitive impairment (MCI) which are at high risk to develop Alzheimer's disease (AD), relative to normal neurological controls. Membrane-bound IDE protein concentrations and activity in the hippocampal formation continued to decrease during the conversion from MCI to mild-severe AD. This selective decrease in hippocampal membrane-bound, but not cytosolic, IDE concentration and activity was tissue specific since no changes in either membrane-bound or cytosolic IDE were found in the occipital cortex of the same cases examined. Most interestingly, the decreased hippocampal membrane-bound IDE protein activity negatively correlated with brain beta-amyloid (Abeta)X-42 content in MCI and in AD brain. The study tentatively suggests that interventions aimed at promoting membrane-bound IDE activities in the brain of MCI cases may help to prevent the onset and possibly the progression into AD through mechanisms involving the clearance of monomeric Abeta from the brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769157     DOI: 10.1016/j.neurobiolaging.2006.05.001

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  48 in total

1.  Partial Loss of the Glutamate Transporter GLT-1 Alters Brain Akt and Insulin Signaling in a Mouse Model of Alzheimer's Disease.

Authors:  Kole D Meeker; James S Meabon; David G Cook
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Notch signaling proteins HES-1 and Hey-1 bind to insulin degrading enzyme (IDE) proximal promoter and repress its transcription and activity: implications for cellular Aβ metabolism.

Authors:  María C Leal; Ezequiel I Surace; María P Holgado; Carina C Ferrari; Rodolfo Tarelli; Fernando Pitossi; Thomas Wisniewski; Eduardo M Castaño; Laura Morelli
Journal:  Biochim Biophys Acta       Date:  2011-10-19

3.  Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.

Authors:  Yaomin Chen; Kun Zhou; Ruishan Wang; Yun Liu; Young-Don Kwak; Tao Ma; Robert C Thompson; Yongbo Zhao; Layton Smith; Laura Gasparini; Zhijun Luo; Huaxi Xu; Francesca-Fang Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

4.  17β-Estradiol regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention.

Authors:  Liqin Zhao; Jia Yao; Zisu Mao; Shuhua Chen; Yan Wang; Roberta Diaz Brinton
Journal:  Neurobiol Aging       Date:  2010-01-06       Impact factor: 4.673

Review 5.  Deregulation of brain insulin signaling in Alzheimer's disease.

Authors:  Yanxing Chen; Yanqiu Deng; Baorong Zhang; Cheng-Xin Gong
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

6.  Transcriptional regulation of insulin-degrading enzyme modulates mitochondrial amyloid β (Aβ) peptide catabolism and functionality.

Authors:  María C Leal; Natalia Magnani; Sergio Villordo; Cristina Marino Buslje; Pablo Evelson; Eduardo M Castaño; Laura Morelli
Journal:  J Biol Chem       Date:  2013-03-22       Impact factor: 5.157

7.  Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease.

Authors:  Mallory Gough; Catherine Parr-Sturgess; Edward Parkin
Journal:  Biochem Res Int       Date:  2010-09-30

8.  Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology.

Authors:  M S Beeri; J Schmeidler; J M Silverman; S Gandy; M Wysocki; C M Hannigan; D P Purohit; G Lesser; H T Grossman; V Haroutunian
Journal:  Neurology       Date:  2008-09-02       Impact factor: 9.910

9.  Molecular basis for the thiol sensitivity of insulin-degrading enzyme.

Authors:  Marie Neant-Fery; Rubén D Garcia-Ordoñez; Todd P Logan; Dennis J Selkoe; Lilin Li; Lael Reinstatler; Malcolm A Leissring
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-08       Impact factor: 11.205

10.  Involvement of insulin-degrading enzyme in the clearance of beta-amyloid at the blood-CSF barrier: Consequences of lead exposure.

Authors:  Mamta Behl; Yanshu Zhang; Wei Zheng
Journal:  Cerebrospinal Fluid Res       Date:  2009-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.